9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
Shares of UK-based rare diseases specialist Mereo BioPharma (Nasdaq: MREO) shot up almost 63% to $3.60 on Friday, after it announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). 19 December 2020
Janux Therapeutics has announced a strategic collaboration with Merck & Co valued at more than $1 billion to develop novel T cell engager (TRACTr) immunotherapies for the treatment of cancer. 18 December 2020
Any doubts that Moderna’s (Nasdaq: MRNA) COVID-19 vaccine is moving swiftly closer to patients in the USA and European Union (EU) have all but vanished this week. 18 December 2020
Privately-held US biopharma firm Cadent Therapeutics has reached a definitive agreement with Novartis, under which the latter will acquire all of the outstanding capital stock of Cadent, and marking the third M&A deal for the Swiss pharma giant this year. 18 December 2020
Coronavirus vaccine co-developer Pfizer has refuted suggestions that there is any delay to its manufacturing and distribution schedule. 18 December 2020
GlaxoSmithKline today said it will co-lead a Series A investment in Adrestia Therapeutics, a UK-based biotechnology company using cutting edge molecular biology to develop precision medicines. 18 December 2020
The US Food and Drug Administration has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. 18 December 2020
The Institute for Clinical and Economic Review (ICER) has published its final recommendations on two drugs in development for non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guerin (BCG) intravesical therapy. 17 December 2020
There are eight mRNA COVID-19 vaccine candidates currently in Phase II or Phase III clinical trials. These vaccines are faster to develop than traditional vaccine formulations, as they use only the genetic sequence of the virus. 17 December 2020
MacroGenics has won US Food and Drug Administration approval for its HER2-targeting biologic Margenza (margetuximab-cmkb) in breast cancer. 17 December 2020
The chief scientific adviser to the US government’s Operation Warp Speed program has said that only 5% to 20% of the roughly 65,000 doses of COVID-19 antibody treatments shipped to states around the country every week end up going to patients. 17 December 2020
US biotech Novavax has announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, the company’s candidate vaccine against COVID-19. 17 December 2020
French biotech firm AB Science yesterday announced that the Phase IIb/III study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer’s disease met its predefined primary endpoint. 17 December 2020
Irish biotech ONK Therapeutics has inked three new exclusive option agreements, boosting its off-the-shelf natural killer (NK) cell therapy platform. 17 December 2020
South Korean contract development and manufacturing organization Samsung Biologics says that John Rim will become its president and chief executive, with immediate effect. 17 December 2020
Sio Gene Therapies has reported positive six-month follow-up data from the low-dose cohort of the company’s dose escalation study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy for the treatment of GM1 gangliosidosis. 16 December 2020
California-based Neuron23, an early-stage biotech focused on developing precision medicines for genetically defined neurological and immunological diseases, has announced its launch backed by a combined $113.5 million Series A and B financing. 16 December 2020
A week on from its review of the Pfizer and BioNTech coronavirus vaccine, the US Food and Drug Administration’s (FDA) overworked Vaccines and Related Biological Products Advisory Committee will consider the case for approving another jab. 16 December 2020
Eli Lilly yesterday revealed that it has signed an agreement to acquire gene therapy company Prevail Therapeutics, with the news sending the latter’s shares roaring up 86% pre-market. 16 December 2020
Following a positive recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October, the European Commission has now granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). 16 December 2020
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024